Why Exicure, Inc.’s (XCUR) Stock Is Down 5.01%
As of Thursday, July 24, Exicure, Inc.’s XCUR share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Exicure, Inc.’s (XCUR) Stock Is Up 5.53%
As of Wednesday, July 23, Exicure, Inc.’s XCUR share price has surged by 5.53%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Exicure, Inc.’s (XCUR) Stock Is Down 14.67%
As of Tuesday, July 22, Exicure, Inc.’s XCUR share price has dipped by 14.67%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Exicure, Inc.’s (XCUR) Stock Is Down 12.68%
As of Tuesday, July 22, Exicure, Inc.’s XCUR share price has dipped by 12.68%, which has investors questioning if this is right time to buy.Omar Beirat
Why Exicure, Inc.’s (XCUR) Stock Is Up 13.44%
As of Monday, July 21, Exicure, Inc.’s XCUR share price has surged by 13.44%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.3 | $251.9 | 7% |
|
| Shares Out (Mil) | 6.4 | 50.8 | 16% |
|
| Institutional Ownership | 26.4% | 92.0% | 12% |
|
| Float (Mil) | 2.9 | 40.5 | 7% |
|
| Beta | 3.54 | 0.95 | 99% |
|
| Avg Daily Volume (000s) | 126 | 447 | 38% |
|
| Price Change (52-week) |
(75.7%) | 54.2% | 8% |
|
| Growth | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | 27.6% | (9.8%) | 82% |
|
| EPS (5yr) | 55.0% | 16.3% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 43.5% | (15.6%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($10) | ($43) | 29% |
|
| EPS (TTM) | ($1.541) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($30) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $16 | $182 | 10% |
|
| Valuation | XCUR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.88 | 2.60 | 78% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | XCUR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (58.5%) | (49.7%) | 10% |
|
| ROE | (145.2%) | (55.4%) | 6% |
|
| Liabilities to Assets | 83.6% | 30.3% | 77% |
|
| F-Score | 1 | 3 | 1% |
|
Exicure, Inc. did not pass any screens on 7/30/2026.
